| Splice site type | Wild type sequence | CV | Mutant type sequence | CV | Variation (%) | |||||
| caaatttcttatagG |
| caaatttcttaGagG |
| 39.2 % |
![]() |
Data for this mutation
| Sample ID | MSH2 | MLH1 | MSH6 | MUTYH | APC |
|---|---|---|---|---|---|
| 19_13168_13168-001_13168- | - | - | - | - | - |
| Analysis | Result | Date | Origin | PMID/dbSNP |
|---|---|---|---|---|
| Clinical phenotype | Multiple primary Lynch-related cancers | 6/10/09 | 19 (Rouen) | |
| Ex vivo analysis | Splicing reporter minigene pCAS: activation of a cryptic splicing acceptor site within exon 15 leading to the deletion of 36 nucleotides or loss of exon 15 | 27/03/09 | 19 (INSERM U1079-Rouen) | |
| In vitro analysis | RT-PCR : probable NMD of the mutated allele (not expressed) | 6/10/09 | 19 (Rouen) | |
| MMR function in tumor cells | MSI / MLH1+MSH2+ | 6/10/09 | 19 (Rouen) |
| Biological significance | Date | Comment |
|---|---|---|
| Likely Causal | 13/12/11 | --- |